头颈部再程放疗后臂丛神经病的预测因素
这项回顾性队列研究分析了48例2015至2022年在单一国家癌症研究所指定综合癌症中心接受常规分割再程放疗的复发性或第二原发头颈部癌患者,中位随访22.7个月,共分析72条接受重叠照射的臂丛。臂丛神经病粗发生率为23%,中位发生时间9.5个月,12和24个月发生率分别为11%和16%。第二程放疗期间同步顺铂和累积EQD2臂丛Dmax≥103 Gy2与臂丛神经病独立相关。
要点
- 再程放疗后臂丛神经病粗发生率为23%,中位9.5个月出现。
- 第二程放疗同步顺铂使臂丛神经病风险显著升高(HR 9.04)。
- 累积EQD2臂丛Dmax≥103 Gy2与臂丛神经病风险显著相关。
核心结论
- 累积EQD2最大剂量和第二程放疗期间同步顺铂与头颈部再程放疗后臂丛神经病发生率升高相关。
研究设计与样本
- 回顾性队列研究纳入48例2015至2022年在单一国家癌症研究所指定综合癌症中心接受常规分割再程放疗的复发性或第二原发头颈部癌患者,中位随访22.7个月。
- 共分析72条接受重叠照射的臂丛,臂丛EQD2按α/β=3 Gy计算。
主要发现
- 臂丛神经病粗发生率为23%,中位发生时间9.5个月,12和24个月发生率分别为11%和16%。
- 单因素分析中,第二程放疗同步顺铂(HR 9.04,95%CI 2.70-30.40,p<0.001)和累积EQD2臂丛Dmax≥103 Gy2(HR 1.10,95%CI 1.04-1.17,p<0.001)与臂丛神经病显著相关,多因素分析中仍显著。
- 臂丛神经病发生率与所有累积体积BP端点V80-V120显著相关,V80≥1.94 cc、V100≥1.35 cc、V120≥0.89 cc和EQD2 Dmax≥103 Gy2时臂丛神经病发生率更高。
关键数值与推荐
- 累积EQD2臂丛Dmax≥103 Gy2与臂丛神经病风险升高相关(HR 1.10,95%CI 1.04-1.17,p<0.001)。
- 第二程放疗同步顺铂与臂丛神经病风险升高相关(HR 9.04,95%CI 2.70-30.40,p<0.001)。
- 臂丛神经病发生率在V80≥1.94 cc、V100≥1.35 cc、V120≥0.89 cc时更高。
临床怎么用
- 头颈部再程放疗计划时应关注臂丛累积EQD2 Dmax及V80-V120体积端点。
- 第二程放疗使用同步顺铂时需更谨慎评估臂丛神经病风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Reirradiation for recurrent or second primary head and neck cancer (HNC) can result in radiation-induced brachial plexopathy (RIBP), a debilitating side effect. This study aims to identify factors associated with the development of RIBP in patients undergoing reirradiation for recurrent or second primary HNC. MATERIALS AND METHODS: This retrospective cohort study included 48 patients treated from 2015 to 2022 at a single National Cancer Institute-Designated Comprehensive Cancer Center, with a median follow-up duration of 22.7 months post-reirradiation. Patients underwent conventionally fractionated reirradiation, and a total of 72 brachial plexi that received overlapping courses of radiation were analyzed. Primary outcomes measured were the incidence of RIBP and factors contributing to increased risk, including EQD2 (equivalent dose in 2 Gy fractions) maximum point dose (Dmax, defined as 0.03 cc) and volumetric brachial plexus (BP) dosimetric endpoints (V80-V120), comorbidities, time between radiation courses, receipt of systemic therapy, and neck dissection. BP EQD2 was calculated using an alpha/beta of 3 Gy. RESULTS: The crude incidence of RIBP was 23 %, occurring at a median of 9.5 months after reirradiation, with 12- and 24-month rates of 11 % and 16 %, respectively. On univariate analysis, concurrent cisplatin during the second course of radiation (hazard ratio [HR] 9.04, 95 % confidence interval [CI]: 2.70-30.40, p < 0.001) and cumulative EQD2 BP Dmax ≥ 103 Gy2 (HR 1.10, CI: 1.04-1.17, p < 0.001) were significantly associated with RIBP. These factors remained significant on multivariable analysis. RIBP incidence was significantly associated with all cumulative volumetric BP endpoints from V80-V120, with higher RIBP rates for V80 ≥ 1.94 cc, V100 ≥ 1.35 cc, V120 ≥ 0.89 cc, and EQD2 Dmax ≥ 103 Gy2. CONCLUSIONS: This study, the largest to date investigating rates of RIBP in patients with HNC treated with conventionally fractionated reirradiation, found that cumulative EQD2 maximum dose, and the use of concurrent cisplatin during the second RT course, were associated with increased rates of RIBP. Understanding these factors may guide clinicians in the setting of reirradiation, potentially leading to improved patient outcomes.
引用
- Dibs K, Gogineni E, Cochran E, et al. Predictors of brachial plexopathy following head and neck reirradiation. Radiother Oncol. 2025. PMID: 40716577. doi:10.1016/j.radonc.2025.111062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。